Last update:

Gastroenterology news

Diseases, Conditions, Syndromes

Widespread use of antacids continues despite long-term health risks, education campaigns

A new UNSW study has found that national initiatives were unsuccessful in reducing prolonged use of anti-acid medicines for gastrointestinal acid-related disorders and more targeted interventions are needed.

Diseases, Conditions, Syndromes

Transient and long-term disruption of gut microbes after antibiotics

Trillions of microbes in the intestine aid human health, including digestion of breast milk, breaking down fiber and helping control the immune system. However, antibiotic treatment is known to disrupt the community structure ...

Immunology

Gut immunity more developed before birth than previously thought

Most biology textbooks explain that the fetal immune system is largely undeveloped and that it learns after being exposed to the world at birth. New research from the University of Pittsburgh School of Medicine and UPMC Children's ...

Inflammatory disorders

FODMAPs diet relieves symptoms of inflammatory bowel disease

New research from King's College London has found that a diet low in fermented carbohydrates has improved certain gut symptoms and improved health-related quality of life for sufferers of inflammatory bowel disease (IBD).

Diseases, Conditions, Syndromes

Recommendations developed for evaluating chronic diarrhea

(HealthDay)—In new American Gastroenterological Association (AGA) clinical practice guidelines, published in the September issue of Gastroenterology, recommendations are presented for laboratory evaluation of chronic watery ...

Gastroenterology

Better methods needed for predicting risk of liver disease

While blood samples can reliably identify people with a low risk of developing severe liver disease, better methods are needed in primary care for identifying people in most need of care. These are some of the conclusions ...

Inflammatory disorders

Two new studies evaluate agents for treating ulcerative colitis

In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures. ...